The U.S. Trade Representative, Jamieson Greer, expressed concerns about Germany's recent legislative efforts to reduce spending on innovative pharmaceuticals, which he described as a 'serious step backwards.' This investigation, launched under Section 301 of the Trade Act, aims to address what the U.S. perceives as unfair practices that could burden American commerce.
Germany's proposed reforms, which include higher discounts for insurance funds from the pharmaceutical industry, have raised alarms among drug manufacturers, leading to warnings about potential withdrawal or delays in introducing new medicines in Germany. has been advocating for fair contributions from its trading partners to support pharmaceutical research and development, especially in light of the Most Favored Nation drug policy introduced by the Trump administration, which links U.S. drug prices to those in other countries.
The outcome of this investigation could have significant implications for the pharmaceutical sector and international trade relations